GRCE · Grace Therapeutics, Inc.

NasdaqHealthcareBiotechnology

Grace Therapeutics Inc Is A Late-Stage Biopharma Company With Drug Candidates Addressing Rare And Orphan Diseases. Its Development Pipeline Consists Of The Following Product Candidates: Gtx-104, A Novel Injectable Formulation Of Nimodipine For The Treatment Of A Rare Disease, Aneurysmal Subarachnoid Hemorrhage (Asah); Gtx-102, Targeted For The Treatment Of Ataxia-Telangiectasia (A-T) In A Pediatric Population; And Gtx-101, A Topical Bio Adhesive Film-Forming Bupivacaine Spray For Postherpetic Neuralgia (Phn), Which Can Be Persistent And Often Causes Debilitating Pain Following Infection By The Shingles Virus. The Company Has One Reportable Operating Segment: The Development And Commercialization Of Pharmaceutical Applications Of Its Patents And Licensed Rights.

HealthcareNasdaqUSMid Float

FLOAT

15.1M

FREE FLOAT %

72%

SHARES O/S

21.0M

MARKET CAP

$40.6M

EXCHANGE

Nasdaq

COUNTRY

GRCE Catalyst History

No catalysts recorded for GRCE yet

Day Trader Sniper hasn't classified a publishable catalyst for GRCE yet. New events appear here as they're scored.

Be early on the next GRCE spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

GRCE · Grace Therapeutics, Inc.

GRCE Catalyst History

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.